Johnson & Johnson (J&J) secured 6th place on the Innovation Index and is the winner of the Invention Index. J&J demonstrated remarkable growth in 2023, with an increase in revenue, R&D spending, and a significant surge in net income. ​

Approvals were granted for TALVEY® (talquetamab), a first-in-class GPRC5D x CD3 bispecific antibody for relapsed and refractory multiple myeloma and AKEEGA®, the first-and-only dual action tablet combining niraparib and abiraterone acetate for deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer. TAR-200, a novel investigational targeted releasing system, also received FDA Breakthrough Therapy Designation for bladder cancer.​​

The Phase 3 Librexia clinical trials program commenced for milvexian, an FXIa inhibitor for the prevention of thrombotic events in ischemic stroke, acute coronary syndrome, and atrial fibrillation. Conducted in collaboration with BMS, this is the most comprehensive FXIa clinical development program to date, with nearly 50,000 patients enrolled across three parallel clinical trials. Milvexian received Fast Track Designation from the FDA for all three indications under evaluation. ​

A marketing authorization application was submitted at the end of 2023 to the EMA for approval of RYBREVANT (amivantamab) in combination with lazertinib, as a first-line treatment for patients with NSCLC and common EGFR mutations. The submission is supported by data from the Phase 3 MARIPOSA study, which demonstrated statistically significant improvement in progression-free survival compared to osimertinib. ​

Phase 3 trials also commenced for JNJ-2113, an IL-23R oral targeted peptide for plaque psoriasis. ​

In 2023, J&J separated from its consumer health business, Kenvue Inc., in a strategic pivot towards pharmaceutical and MedTech solutions. In MedTech, growth was seen across orthopedics, surgery, interventional solutions, and vision. ​

With 19 US and EU filings in 2023, J&J set high expectations for continued progress and success in the year ahead. ​

Johnson and Johnson – Invention winner

''Johnson & Johnson is leading where medicine is going by translating novel concepts into differentiated and transformational products. We begin therapeutic invention with the end in mind, addressing unmet patient needs and harnessing science to solve challenges that others believe are impossible. Invention thrives at Johnson & Johnson thanks to our world-class talent and expansive toolkit of modalities, spanning small molecules, biologics and cell and genomic therapies.”

– Richard Tillyer, Ph.D., Global Head, Discovery, Product Development & Supply, Johnson & Johnson Innovative Medicine

See the full results and download the report here